17.56
-0.24 (-1.35%)
| Previous Close | 17.80 |
| Open | 17.88 |
| Volume | 5,064,572 |
| Avg. Volume (3M) | 2,217,001 |
| Market Cap | 2,897,876,224 |
| Price / Book | 3.07 |
| 52 Weeks Range | |
| Earnings Date | 7 May 2026 |
| Diluted EPS (TTM) | -3.61 |
| Total Debt/Equity (MRQ) | 3.49% |
| Current Ratio (MRQ) | 20.35 |
| Operating Cash Flow (TTM) | -319.72 M |
| Levered Free Cash Flow (TTM) | -176.84 M |
| Return on Assets (TTM) | -39.92% |
| Return on Equity (TTM) | -64.01% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | Dyne Therapeutics, Inc. | Bullish | Bearish |
AIStockmoo Score
| Analyst Consensus | 1.5 |
| Insider Activity | NA |
| Price Volatility | 1.0 |
| Technical Moving Averages | 1.0 |
| Technical Oscillators | 4.0 |
| Average | 1.88 |
|
Dyne Therapeutics Inc is a clinical-stage neuromuscular disease company focused on discovering and advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases. Its FORCE platform develops targeted therapeutics that are designed to overcome limitations in delivery to muscle tissue and the central nervous system, or CNS. Its FORCE platform therapeutics consist of a payload that is rationally designed to target the genetic basis of the disease are seeking to treat, a linker, and an antigen-binding fragment, that attaches to the payload using the linker. Its Pipeline includes DYNE-101, DYNE-251, DYNE-302, and DYNE-401. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 0.56% |
| % Held by Institutions | 110.24% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 50.00 (HC Wainwright & Co., 184.74%) | Buy |
| Median | 42.50 (142.03%) | |
| Low | 16.00 (JP Morgan, -8.88%) | Hold |
| Average | 37.75 (114.98%) | |
| Total | 3 Buy, 1 Hold | |
| Avg. Price @ Call | 15.87 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Chardan Capital | 09 Mar 2026 | 38.00 (116.40%) | Buy | 17.69 |
| 03 Mar 2026 | 38.00 (116.40%) | Buy | 14.60 | |
| HC Wainwright & Co. | 03 Mar 2026 | 50.00 (184.74%) | Buy | 14.60 |
| Morgan Stanley | 03 Mar 2026 | 47.00 (167.65%) | Buy | 14.60 |
| JP Morgan | 20 Jan 2026 | 16.00 (-8.88%) | Hold | 16.58 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 06 Mar 2026 | CNBC | FDA reversals leave investors worrying about the fates of other experimental drugs |
| 20 Jan 2026 | Announcement | Dyne Therapeutics Receives Orphan Drug Designation in Japan for Zeleciment Basivarsen (DYNE-101) for Myotonic Dystrophy Type 1 |
| 07 Jan 2026 | Announcement | Dyne Therapeutics to Present at 44th Annual J.P. Morgan Healthcare Conference |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |